GlassScriptPhysician profile
Elizabeth Fox
NPI 1891303046
$2,181.91
in general payments reported to CMS, 2019-2025
17 companies · $490 in 2025
The $490 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $84.92 · 2023: $707 · 2024: $900 · 2025: $490.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,097.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,096.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $500.08 | 2023-2025 | |
| Neos Therapeutics, LP | $389.72 | 2023-2025 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Almatica Pharma LLC | $193.21 | 2023-2025 | Loreev Xr, Gralise |
| Otsuka America Pharmaceutical, INC. | $186.40 | 2023-2025 | Rexulti, Abilify Maintena |
| Alkermes, INC. | $129.15 | 2022-2024 | Aristada, Lybalvi, Vivitrol |
| Lundbeck LLC | $129.15 | 2023-2025 | Rexulti, Abilify Maintena |
| Axsome Therapeutics, INC. | $111.51 | 2023-2024 | Auvelity, Sunosi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $104.77 | 2023-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $92.83 | 2023-2024 | Invega Trinza, Invega Sustenna, Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $68.73 | 2023-2024 | Trintellix |
| Corium, LLC | $63.00 | 2024-2025 | Azstarys |
| Vanda Pharmaceuticals INC. | $59.51 | 2023-2024 | Hetlioz, Fanapt |
| Teva Pharmaceuticals USA, INC. | $54.27 | 2023-2024 | Austedo Xr, Uzedy |
| Tris Pharma INC | $50.36 | 2023-2024 | Dyanavel Xr |
| Supernus Pharmaceuticals, INC. | $19.80 | 2024 | Qelbree |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $14.99 | 2024 | Xelstrym |
| Ironshore Pharmaceuticals INC. | $14.43 | 2023 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Fox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.